Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

-0.03 (-0.55%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
163,176 shs
Average Volume
198,420 shs
Market Capitalization
$145.68 million
P/E Ratio
Dividend Yield
Price Target

Syros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
156.9% Upside
$14.00 Price Target
Short Interest
7.79% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.49mentions of Syros Pharmaceuticals in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$747 Sold Last Quarter
Proj. Earnings Growth
From ($3.56) to ($3.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

113th out of 922 stocks

Pharmaceutical Preparations Industry

40th out of 425 stocks

SYRS stock logo

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Stock Price History

SYRS Stock News Headlines Upgrades Syros Pharmaceuticals (NASDAQ:SYRS) to Hold
Here's what Wall Street expects from Syros Pharmaceuticals's earnings
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Syros Pharmaceuticals earnings preview: what Wall Street is expecting
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$9.94 million
Book Value
$0.56 per share


Free Float
Market Cap
$145.68 million
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Richard A. Young Ph.D. (Age 70)
    Scientific Founder, Member of Scientific Advisory Board & Director
    Comp: $108.37k
  • Dr. David A. Roth M.D. (Age 61)
    Chief Medical Officer
    Comp: $679.52k
  • Mr. Conley Chee (Age 54)
    CEO, President & Director
  • Dr. James E. Bradner M.D. (Age 52)
  • Dr. Nathanael S. Gray Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Jason Haas (Age 56)
    Chief Financial Officer
    Comp: $457.22k
  • Ms. Karen Hunady M.S.
    Director of Corporate Communications & Investor Relations
  • Mr. Gerald E. Quirk Esq. (Age 56)
    J.D., Chief Legal Officer & Head of Business Development
    Comp: $127.07k
  • Ms. Lisa Roberts
    Vice President of Human Resources
  • Ms. Kristin Stephens (Age 51)
    Chief Development Officer

SYRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 1-year price targets for Syros Pharmaceuticals' shares. Their SYRS share price targets range from $13.00 to $15.00. On average, they predict the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 156.9% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2024?

Syros Pharmaceuticals' stock was trading at $7.79 on January 1st, 2024. Since then, SYRS shares have decreased by 30.0% and is now trading at $5.45.
View the best growth stocks for 2024 here

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our SYRS earnings forecast

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its earnings results on Tuesday, May, 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.10. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 395.36% and a negative net margin of 1,656.34%. During the same quarter last year, the business earned ($0.85) earnings per share.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.47%), Kennedy Capital Management LLC (1.51%), Assenagon Asset Management S.A. (0.64%) and Acadian Asset Management LLC (0.06%). Insiders that own company stock include David Roth, Eric R Olson, Srinivas Akkaraju and Timothy Tyson.
View institutional ownership trends

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYRS) was last updated on 5/18/2024 by Staff

From Our Partners